The power crisis in China may disrupt the Indian pharmaceuticals market if it persists, Business Standard reported on Thursday, quoting people in the domestic industry.
Prices of active pharmaceutical ingredients (APIs), or raw materials used to make drugs that are mostly imported from China, have gone through the roof amid delays in shipments, data showed. Indian pharma companies import 66-70% of their bulk drug requirements from China, the report said.
The prices of Penicillin-G from China have gone up from $14 per unit to $26 in just one month, the report said, quoting Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), a lobby for big pharma firms in India.
Read the full report: Business Standard.